SCIPIO results triple projections
Data from U of L trial published today in The Lancet and presented at American Heart Association Scientific Sessions
Dr. Roberto Bolli (right) joined by the first pair of SCIPIO patients Jim Dearing (left) and Mike Jones (middle).
Patients suffering from heart failure due to a previous myocardial infarction showed an average of 12 percent improvement one year following an investigative treatment that involved infusing them with their own stem cells.
The results triple the 4 percent improvement average the researchers projected for the Phase I trial.
The research team, led by Dr. Roberto Bolli of the University of Louisville and Dr. Piero Anversa at Brigham and Women's Hospital/Harvard Medical School in Boston, conducted the trial, called "SCIPIO" (Stem Cell Infusion in Patients with Ischemic CardiOmyopathy).
Results of the trial were published Nov. 14, 2011, in The Lancet and concurrently presented at the American Heart Association Scientific Sessions in Orlando, Fla.
They are the first report of administering subjects' own cardiac stem cells in humans; previous studies have used stem cells harvested from bone marrow.
► READ FULL STORY
► READ AHA PRESENTATION ABSTRACT
RELATED ARTICLES
-
Bolli, SCIPIO featured by WHAS-11 (Nov. 10, 2011)
-
U of L, Bolli score again (Sept. 9, 2011)
-
Bolli, U of L to lead multi-center cardioprotective study (Feb. 4, 2011)
-
Cardiac stem cells safe, effective in heart failure treatment (Nov. 15, 2010)
